Prostate-specific antigen measured 3months after radical prostatectomy as a new predictor of biochemical recurrence
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490317 | ||
| 003 | CHVBK | ||
| 005 | 20210128100504.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0681-7 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0681-7 | ||
| 245 | 0 | 0 | |a Prostate-specific antigen measured 3months after radical prostatectomy as a new predictor of biochemical recurrence |h [Elektronische Daten] |c [Hitoshi Inoue, Kensaku Nishimura, Seiji Yamaguchi, Norio Nonomura, Tsuneo Hara] |
| 520 | 3 | |a Background: This study was undertaken to investigate if the prostate-specific antigen (PSA) level measured 3months after radical prostatectomy (RP) is a predictor of biochemical recurrence (BCR)-free survival. Methods: We retrospectively reviewed the clinicopathologic data of 174 patients with a follow-up of at least 3years after RP for clinically localized prostate cancer. None of the patients received neoadjuvant/adjuvant therapy. Subjects were categorized according to PSA level 3months after RP (3M-PSA): <0.010ng/mL (group 1; n=119) or 0.010-0.100ng/mL (group 2; n=55). BCR was defined as two consecutive rises in PSA level ≥0.2ng/mL. Results: At a median follow-up of 69.5months (range 36-113months), 32 (18.4%) patients experienced BCR. The median time to BCR was 16months (range 4-98months) after RP. The 5-year BCR-free survival rate was 92.6 and 57.4% in groups 1 and 2, respectively. Patients in group 1 had a significantly higher BCR-free survival rate than those in group 2 (log-rank P<0.001). According to the Cox proportional hazards model, patients with a 3M-PSA level of <0.010ng/mL were at lower risk for BCR (P<0.001), along with pathologic Gleason sum 6 (P=0.028). PSA nadir level after RP was also a risk factor for BCR (log-rank P<0.001). Area under the receiver operating characteristic curve for 3M-PSA to predict BCR was almost equivalent to that for the PSA nadir level (0.855 vs. 0.849). Conclusions: 3M-PSA is an independent predictor of BCR-free survival. Our findings might be used for a risk-adjusted follow-up protocol. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Prostate cancer |2 nationallicence | |
| 690 | 7 | |a Prostate-specific antigen |2 nationallicence | |
| 690 | 7 | |a Radical prostatectomy |2 nationallicence | |
| 690 | 7 | |a Predictor |2 nationallicence | |
| 690 | 7 | |a Biochemical recurrence |2 nationallicence | |
| 700 | 1 | |a Inoue |D Hitoshi |u Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan |4 aut | |
| 700 | 1 | |a Nishimura |D Kensaku |u Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan |4 aut | |
| 700 | 1 | |a Yamaguchi |D Seiji |u Department of Urology, Osaka General Medical Center, Osaka, Japan |4 aut | |
| 700 | 1 | |a Nonomura |D Norio |u Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan |4 aut | |
| 700 | 1 | |a Hara |D Tsuneo |u Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 171-175 |x 1341-9625 |q 20:1<171 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0681-7 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0681-7 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Inoue |D Hitoshi |u Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nishimura |D Kensaku |u Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yamaguchi |D Seiji |u Department of Urology, Osaka General Medical Center, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nonomura |D Norio |u Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hara |D Tsuneo |u Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 171-175 |x 1341-9625 |q 20:1<171 |1 2015 |2 20 |o 10147 | ||